Clinical Articles

The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF

1) Institute of Pharmacology and Experimental Therapeutics/IBILI, Faculty of Medicine, University of Coimbra, Portugal, Portugal
2) CNC.IBILI - University of Coimbra, Portugal
3) CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal
4) III-Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Portugal
5) Achucarro Basque Center for Neuroscience, Science Park of the University of the Basque Country (UPV/EHU) Leioa, Spain
6) Ikerbasque Basque Foundation for Science, Bilbao, Bizkaia, Spain
7) Faculty of Pharmacy, University of Coimbra, Portugal
8) Ministry of Education, Maputo, Mozambique
9) Faculty of Veterinary Medicine, Lisbon University, Lisbon, Portugal, Portugal
10) Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Italy
11) Institute of Biochemistry, Faculty of Medicine, University of Coimbra, Portugal

The poster was presented on July 3rd 2018 at the World Congress of Pharmacognosy 2018 in Kyoto Japan with the following conclusions:

1) CV biomass oral administration promotes a significant increase in dendritic length and branching and total dendritic volume of immature neurons, suggesting a positive effect in the hippocampal neurogenic reserve.
2) Increase of β-catenin levels both in nucleus and cytoplasm of DG immature neurons, suggests that Wnt/β-catenin signalling plays an important role in the CV positive effect on the dendritic complexity of hippocampal newly-generated neurons.
3) The so far unexplored neurogenic potential of CV supplementation emerges as a possible preventive strategy for different neurological conditions.